COVID-19 vaccination coverage by company size and the effects of socioeconomic factors and workplace vaccination in Japan: a cohort study

Koji Mori^{1*}, Takahiro Mori¹, Tomohisa Nagata¹, Hajime Ando², Ayako Hino³, Seiichiro Tateishi⁴, Mayumi Tsuji⁵, Keiji Muramatsu⁶, Yoshihisa Fujino⁷ for the CORoNa Work Project

¹Department of Occupational Health Practice and Management, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan

²Department of Work Systems and Health, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan ³Department of Mental Health, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan

⁴Department of Occupational Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Yahatanishi-ku, Kitakyushu 807-8555, Japan

⁵ Department of Environmental Health, School of Medicine, University of
Occupational and Environmental Health, Japan, 1-1 Iseigaoka,
Yahatanishi-ku, Kitakyushu 807-8555, Japan
⁶ Department of Public Health, School of Medicine, University of
Occupational and Environmental Health, Japan, 1-1 Iseigaoka,
Yahatanishi-ku, Kitakyushu 807-8555, Japan
⁷ Department of Environmental Epidemiology, Institute of Industrial
Ecological Sciences, University of Occupational and Environmental
Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555,
Japan

* Corresponding author: Koji Mori, kmori@med.uoeh-u.ac.jp

Short title: COVID-19 vaccination coverage by company size

Total word count: 3369 (6400 max)

1 Abstract

2	Background: Vaccination is considered the most effective control measure against COVID-
3	19. Vaccine hesitancy and equitable vaccine allocation are important challenges to
4	disseminating developed vaccines. To promote COVID-19 vaccination coverage, the
5	government of Japan established the workplace vaccination program. However, while it
6	appears that the program was effective in overcoming vaccine hesitancy, the program may have
7	hindered the equitable allocation of vaccines because it mainly focused on employees of large
8	companies. We investigated the relationship between company size and COVID-19 vaccination
9	completion status of employees and the impact of the workplace vaccination program on this
10	relationship.
11	Methods: We conducted an internet-based prospective cohort study from December 2020
11 12	Methods: We conducted an internet-based prospective cohort study from December 2020 (baseline) to December 2021. The data were collected using a self-administered questionnaire
12	(baseline) to December 2021. The data were collected using a self-administered questionnaire
12 13	(baseline) to December 2021. The data were collected using a self-administered questionnaire survey. Briefly, 27,036 workers completed the questionnaire at baseline and 18,560 at follow-
12 13 14	(baseline) to December 2021. The data were collected using a self-administered questionnaire survey. Briefly, 27,036 workers completed the questionnaire at baseline and 18,560 at follow-up. After excluding ineligible respondents, we finally analyzed the data from 15,829
12 13 14 15	(baseline) to December 2021. The data were collected using a self-administered questionnaire survey. Briefly, 27,036 workers completed the questionnaire at baseline and 18,560 at follow- up. After excluding ineligible respondents, we finally analyzed the data from 15,829 participants. At baseline, the participants were asked about the size of the company they worked
12 13 14 15 16	(baseline) to December 2021. The data were collected using a self-administered questionnaire survey. Briefly, 27,036 workers completed the questionnaire at baseline and 18,560 at follow- up. After excluding ineligible respondents, we finally analyzed the data from 15,829 participants. At baseline, the participants were asked about the size of the company they worked for, and at follow-up they were asked about the month in which they received their second

20	for large-company employees in the sex- and age-adjusted model. This difference decreased
21	after adjusting for socioeconomic factors, and there was no significant difference after
22	adjusting for the availability of a company-arranged vaccination opportunity.
23	Conclusions: The workplace vaccination program implemented in Japan to control the
24	COVID-19 pandemic may have been effective in overcoming vaccine hesitancy in workers;
25	however, it may have caused an inequitable allocation of vaccines between companies of
26	different sizes. Because people who worked for small companies were less likely to be
27	vaccinated, it will be necessary to enhance support of vaccination for this population in the
28	event of future infectious disease outbreaks.
29	
30	Trial registration: Not applicable.
31	
32	Keywords: COVID-19, Vaccine hesitancy, Equitable allocation, Workplace vaccination,
33	Company size, Socioeconomic factors

35 Introduction

36	Vaccination programs are underway worldwide because vaccination is the most effective
37	measure to control the coronavirus disease 2019 (COVID-19) pandemic, which was declared
38	by the World Health Organization (WHO) in March 2020. Since the outbreak of COVID-19 in
39	China in December 2019 [1], various types of vaccines have been developed in a short period
40	of time [2]. Some of these are mRNA vaccines, representing a new type of vaccine technology
41	[3].

Disseminating vaccines presents many challenges, among which vaccine hesitancy 42 and equitable allocation are prominent. Vaccine hesitancy, defined as the "delay in acceptance" 43 or refusal of vaccination despite the availability of vaccination services" is considered a major 44 45 public health challenge in infectious disease control because it delays vaccination of the 46 population and inhibits the acquisition of herd immunity [4]. Various factors, including 47 socioeconomic [5] and psychological factors [4], have been found to contribute to people's vaccine hesitancy. Such factors have also been examined in the context of COVID-19 48 vaccination [6.7]. The equitable allocation of vaccines is based on maintaining equity in the 49 50 order of vaccination according to risk regardless of social status, for example by starting with healthcare workers and those at higher risk of serious illness [8]. 51

52 In Japan, the majority of the population had some level of initial vaccine hesitancy to 53 receive a COVID-19 vaccine [9,10]. Nevertheless, by the end of December 2021,

54	approximately 80% of the population had received two vaccine doses [11]. In Japan, COVID-
55	19 vaccination efforts began on February 17, 2021 using two mRNA vaccines: one from Pfizer
56	Inc. and one from Moderna Inc. In consideration of equitable vaccine allocation, the
57	vaccination of healthcare workers was followed by the vaccination of older adults [12].
58	Thereafter, vaccination progressed through the general population in stages according to age.
59	An aspect of COVID-19 vaccination in Japan has been the availability of vaccination
60	at workplaces in addition to community settings provided by municipalities and clinics [12].
61	Compared with other developed countries, the start of the vaccination program was delayed in
62	Japan. To make up for this delay, the government appointed a minister to be in charge and set
63	a goal of administering one million vaccinations per day. Part of the vaccination strategy was
64	to implement the opportunity for workplace vaccination, which was conducted mainly by
65	occupational health professionals such as occupational physicians and occupational health
66	nurses. As a result, 9,654,000 people received their second vaccine dose through the workplace
67	vaccination program, which started on June 21, 2021 [13]. Workplace vaccination, which
68	provides a convenient vaccination opportunity, may have reduced vaccine hesitancy because
69	several psychological and social factors can positively influence a person's vaccination
70	decision.

The workplace COVID-19 vaccination program in Japan, however, may have
 negatively affected the equitable allocation of vaccine doses. This program primarily targeted

73	large companies, with a minimum of 2,000 doses to be delivered to a single location (i.e., an
74	expected vaccination coverage of at least 1,000 persons [13]). Thus, there were barriers to its
75	implementation in small and medium-sized companies. Therefore, company size may have
76	affected the timing and coverage of employees receiving the second COVID-19 vaccine dose.
77	We hypothesized that while the workplace vaccination program facilitated COVID-19
78	vaccination, there was a size-dependent difference among companies in the timing of
79	employees receiving the second vaccine dose and that this difference was influenced by the
80	availability of a company-arranged vaccination opportunity. In a survey conducted in Japan
81	during the COVID-19 pandemic, there were differences in the implementation of infection
82	control measures and the opportunity to work remotely depending on the size of the company
83	[14,15]. Disparities in occupational health measures, such as workplace environmental and
84	health measures, have arisen and depend on the size of the company. Such disparities have also
85	been found in the establishment of COVID-19 countermeasures. Therefore, rather than the
86	government's workplace vaccination program ensuring vaccine equity, this program may have
87	increased disparities in infection risk because of differences in the completion of COVID-19
88	vaccination based on company size.
89	We conducted a prospective cohort study to examine the relationship between

We conducted a prospective cohort study to examine the relationship between company size and COVID-19 vaccination completion and the impact of the workplace vaccination program on this relationship, focusing on the period between July and December

92 2021, when the general population in Japan was receiving the second vaccine dose.

93

94 Methods

95 Study design and participants

This study was a part of the Collaborative Online Research on Novel-coronavirus Work Study 96 97 (the CORoNa Work Study) and was conducted using a prospective cohort study design. The survey was commissioned to the internet survey company Cross Marketing Inc. (Tokyo Japan), 98 99 and the data were collected using a self-administered online questionnaire. All participants 100 gave informed consent, and the study was approved by the ethics committee of the University 101 of Occupational and Environmental Health, Japan (approval number: R2-079 and R3-006). 102 The baseline survey was conducted from December 22 to 25, 2020. The protocol for 103 the baseline survey has been previously reported in detail [16]. The participants were aged 20-104 65 years and were employed at the time of the baseline survey (N=33,087). Participants were 105 included using cluster sampling by sex, age, region, and occupation. A total of 27,036 106 participants were included after excluding ineligible individuals: those for which no data on 107 company size was available, who worked in the medical or welfare sectors, or who were older 108 than 65 at the time of the follow-up survey.

109 The follow-up survey was conducted from December 15 to 22, 2021, 1 year after 110 baseline. A total of 18,560 participants responded to the survey. Among them, respondents were excluded if they were unemployed, over 65 years of age, or employed in the health or welfare
sector and thus eligible for priority vaccination at the time of the follow-up survey. Finally,
15,829 participants were included in the analysis. Figure 1 shows the flow diagram for this
study.

115

116 Second COVID-19 vaccination dose status

In the follow-up survey, we asked participants, "In what month did you receive the second 117 118 COVID-19 vaccination?" Participants were requested to choose one of 12 options: the months 119 of February 2021 through December 2021, or "have not received." We then created a variable 120 for completion status for each month after July. For example, completion by the end of 121 September was defined as having received a second COVID-19 vaccine dose in any of the 122 months from February through September. If a participant received the second vaccine dose in 123 September, completion by July or August would be coded "no" but completion by September, October, November, and December would be coded "yes". 124

125

126 Company size

In the baseline survey, we asked participants, "How many employees are there at your company?" The participants could choose one of 10 options: 1 person (self-employed) or 2–4, 5–9, 10–29, 30–49, 50–99, 100–499, 500–999, 1000–9999, or 10,000 or more persons. We

130	classified the responses into three categories: those who worked for small (1-49), medium-
131	sized (50-999), or large (1,000 or more) companies. This classification was made because
132	under the Industrial Safety and Health Act, the obligation to establish an occupational health
133	management system differs depending on the size of the worksite [17]. Furthermore, the
134	government-provided workplace vaccination program was eligible for locations that could
135	vaccinate at least 1,000 people [13].
136	
137	Company-arranged vaccination opportunity
138	In the follow-up survey, we asked participants, "Has your company arranged an opportunity to
139	receive the COVID-19 vaccine at the workplace, whether or not you took advantage of the
140	opportunity?" Participants could choose one of three response options: yes, no, or unknown.
141	We regarded "yes" to indicate that the vaccination opportunity was arranged, and the other
142	answers to indicate that this was not arranged.
143	
144	Assessment of covariates
145	Participant characteristics were collected at baseline. The covariates included socioeconomic
146	factors, occupation, and industry. Age was classified into five groups: 20-29, 30-39, 40-49,
147	50-59, and 60-65 years. Annual household income was classified into five categories: <2.00
148	million Japanese yen (JPY), 2.00–3.99 million JPY, 4.00–5.99 million JPY, 6.00–7.99 million

149 JPY, and 8.00 million JPY or greater. Educational background was classified into three 150 categories: junior high or high school, vocational school or college, and university or graduate 151 school. Marital status was classified into three categories: married, divorced or widowed, and unmarried. Occupation was classified into 10 categories: general employee; manager; 152 executive manager; public employee, faculty member, or non-profit organization employee; 153 154 temporary or contract employee; self-employed; small office/home office; agriculture, forestry, or fishing; professional occupation (e.g., lawyer, tax accountant); and other occupations. 155 Participants could choose one of 22 options for their work industry, which was then classified 156 157 into nine categories based on the International Standard Industrial Classification of All Economic Activities: manufacturing, public service, information and communication, 158 159 wholesale and retail, food service, education and religion, finance and insurance, construction, 160 and others.

161

162 Statistical analysis

The odds ratios (ORs) for the association between company size and completion of the second COVID-19 vaccine dose were estimated using a multilevel logistic model nested in the prefecture of residence to account for regional variability. The multivariate model was adjusted for sex and age (Model 1) and additionally adjusted for annual household income, educational background, marital status, occupation, and industry (Model 2). Finally, the model was adjusted

168 for company-arranged vaccination opportunity (Model 3).

169 A *p*-value of less than 0.05 was considered statistically significant. All analyses were 170 conducted using Stata (Stata Statistical Software: Release 16; StataCorp LLC, College Station, TX, USA). 171 172 Results 173 Table 1 shows the participant characteristics by company size. Of the 15,829 participants, 4,272 174(27%) worked for a large company, 5,117 (32%) for a medium-sized company, and 6,440 (41%) 175 176 for a small company. As the company size increased, the percentage of participants with a high 177 annual household income and a high educational background level increased. Furthermore, as 178 the company size increased, the opportunity for company-arranged vaccination increased: 56% 179 for large companies, 35% for medium-sized companies, and 14% for small companies. 180 <Insert Table 1> 181 Table 2 shows the ORs for the association between company size and completion of 182 the second COVID-19 dose by month. In the model adjusted only for age and sex (Model 1), 183 participants who worked for a medium-sized company were significantly less likely to 184 complete the second dose by August (OR=0.87, 95% CI: 0.79–0.94, p=0.001) and September 185 (OR=0.86, 95% CI: 0.78–0.93, p<0.001) than those who worked for a large company. For small companies, the ORs decreased throughout the entire observation period, from July to December. 186

187	In the model adjusted for the main socioeconomic factors (Model 2), the ORs for medium-
188	sized and small companies tended to approach 1. For August and September, this tendency
189	remained, but no significant difference was observed for the medium-sized companies. After
190	adjusting for company-arranged vaccination opportunity (Model 3), the significant difference
191	between small and large companies disappeared for the entire period analyzed. However, after
192	October, participants who worked for medium-sized companies were significantly more likely
193	to have received the second vaccine dose than those who worked for large companies (OR=1.14
194	95% CI: 1.01–1.28, p=<0.029). In each month throughout the observation period, those who
195	had a company-arranged vaccination opportunity were significantly more likely to have
196	received the second vaccine dose.
197	<insert 2="" table=""></insert>

198

199 Discussion

This study showed that employees of smaller companies were less likely to have received a second COVID-19 vaccine dose. In the months after the start of the workplace vaccination program, the second dose completion rate of participants who worked for medium-sized companies was lower than that of those who worked for large companies, but this difference disappeared later in the observation period. The significant difference in completion rate between small company employees and large company employees remained throughout the

206	observation period. The difference between large and medium-sized company employees could
207	mostly be explained by differences in socioeconomic factors. However, the difference between
208	the small and large company employees could not be explained by those factors alone, although
209	adjusting for the socioeconomic factors reduced the difference. After adjusting for company-
210	arranged vaccination opportunity, the difference in employee second dose completion rate
211	between large and small companies disappeared. Furthermore, medium-size companies had
212	higher vaccine completion coverage than large companies in the latter half of the observation
213	period.
214	The presence of vaccine hesitancy owing to a lack of trust in vaccination and other
215	factors has been a challenge to achieving herd immunity through vaccination. Socioeconomic
216	factors have been found to affect vaccination intention and uptake of other vaccines, such as
217	the seasonal influenza vaccine [18] and the H1N1 vaccine [19]. The effects of socioeconomic
218	factors on vaccination intention for the COVID-19 vaccine have also been examined [6,7].
219	Studies have generally found a positive association between vaccine uptake and annual income
220	and educational background, although some studies have shown inverse associations [20, 21].
221	Several studies have found differences in willingness to vaccinate depending on one's
222	occupation and industry [22-24]. In the current study, after adjusting for socioeconomic factors,
223	the difference in vaccination completion rate among employees of medium and large
224	companies disappeared. After these adjustments, the difference between employees of small

and large companies also became smaller. These findings suggest that socioeconomic factors
 affect the association between COVID-19 vaccination and company size in Japan.

227 In the present study, it was observed that participants who had a company-arranged vaccination opportunity were significantly more likely to have received the second vaccine 228 dose, and after adjusting the model for the presence of a company-arranged vaccination 229 230 opportunity, no significant difference in the second dose completion rate was found between employees of small and large companies for all months. These results suggests that the 231 government's implementation of the workplace vaccination program had a positive impact on 232 the vaccination acceptance of employees who worked for companies that participated in the 233 234 program. The company-arranged vaccination opportunities may have decreased vaccine 235 hesitancy and increased vaccination coverage. To evaluate the psychosocial factors influencing 236 vaccine hesitancy, in 2011, the WHO Strategic Advisory Group of Experts proposed the "3C" 237 model [4], which stands for "Confidence", "Convenience", and "Complacency." German researchers subsequently proposed the "5C" model, substituting "Constraints" for 238 "Convenience" and adding "Calculation" and "Collective responsibility" [25]. Company-239 arranged vaccination opportunities are thought to increase people's confidence in a vaccine, 240 241 and the availability of the vaccine at or near their workplace increases its convenience. In 242 addition, social environmental factors, such as social norms and herding effects, have been suggested to affect one's vaccine intention [26,27]. The workplace vaccination program 243

facilitated employees' vaccination behavior to be shared among coworkers and supervisors, which may have had a direct impact on the social norms and herding effect. Previous studies on seasonal influenza vaccination in the U.S. have reported that workplace vaccination practices and recommendations are associated with higher vaccination coverage [28].

The influence of socioeconomic factors and company-arranged vaccination 248 249 opportunities on vaccination coverage has implications for the equitable allocation of vaccines. In the workplace vaccination program, the government invited companies that wished to 250 251 implement the program on the premise that at least 1,000 people could be vaccinated at a single location [13]. Multiple small companies could apply if they could jointly secure more than 252 253 1,000 people willing to be vaccinated. However, because it was necessary to arrange venues 254 and medical personnel for the vaccination event and to coordinate costs, program utilization 255 may vary greatly depending on company size. In Japan, employers with less than 50 full-time staff are not obligated to appoint an occupational health physician or health supervisor or to 256 establish a health committee. This lack of obligation means that workers in small companies 257 often do not have occupational health services available to them [17]. In addition, during the 258 259 COVID-19 pandemic in Japan, there were marked differences among companies of different sizes in the implementation of remote work and infection control measures [14,15]. The 260 261 Japanese government's workplace vaccination program may have contributed to health disparities. Therefore, the pros and cons of a workplace vaccination program and the methods 262

used to realize it warrant further discussion to ensure a more equitable implementation in future
infectious disease outbreaks.

It is unclear why there was significantly higher vaccination completion among 265 participants who worked for medium-sized companies compared with those who worked for 266 large companies after October 2021 in the model adjusted for both socioeconomic factors and 267 268 company-arranged vaccination opportunity. One possible explanation is that many employees of large companies were located in offices other than the headquarters and therefore had 269 difficulty accessing the company-arranged vaccination opportunity. Another possibility is that, 270 although COVID-19 vaccination was voluntary, medium-sized companies are often in a weaker 271 272 business position than larger companies, and therefore they may have been more influenced by 273 pressure from clients to vaccinate their employees in order to continue doing business. 274This study had several limitations. First, the survey was conducted via the internet, so generalizations should be made with caution. However, we attempted to reduce any bias by 275 using cluster sampling with stratification by sex, region, and job type. Second, the study was 276 likely affected by recall bias. The earlier vaccination was completed, the more time had elapsed 277 278 by the time of the survey, which may have caused recall bias. Third, the timing of the follow-279 up survey might have affected the responses to the question of vaccination status in the last 280 month, December. If a person received their second vaccine dose in the last week of December

281 (after filling out the follow-up survey), they may have answered "unvaccinated" when asked

282 about their vaccination status in the follow-up survey. However, the impact of this situation was likely small because second-dose vaccination was nearly complete in both the community 283 284 and workplace programs by the end of November, and less than 1% of the respondents received their second vaccine dose in December. 285 286 Conclusion 287 During the period when COVID-19 vaccinations were being administered to the general 288 population in Japan, the coverage of receiving a second COVID-19 vaccine dose was 289 290 significantly lower for those who worked for small companies than for those who worked for 291 large companies. This difference could mostly be explained by socioeconomic factors and the 292 availability of a vaccination opportunity arranged by the employer. In the event of future 293 infectious disease outbreaks, it will be necessary to enhance support of vaccination for the employees of small companies. 294 295 List of Abbreviations 296 COVID-19: coronavirus diseases 2019; mRNA: messenger RNA; WHO: World Health 297 298 Organization; JPN: Japanese yen; OR: odds ratio; CI: confidence interval. 299

301		References						
302	1.	Lu R, Zhao X, Li J, Niu P, Yang B, Peihua N, et al. Genomic characterisation and						
303		epidemiology of 2019 novel coronavirus: implications for virus origins and receptor						
304		binding. Lancet. 2020;395:565-74. https://doi.org/10.1016/S0140-6736(20)30251-83-16.						
305	2.	Conte C, Sogni F, Affanni P, Veronesi L, Argentiero A, Esposito S. Vaccines against						
306		Coronaviruses: The State of the Art. Vaccines. 2020;8:309.						
307		https://doi.org/10.3390/vaccines8020309						
308	3.	Jin Y, Hou C, Li Y, Zheng K, Wan C. mRNA Vaccine: How to Meet the Challenge of SARS-						
309		CoV-2. Front Immunol. 2022;12:821538. <u>https://doi.org/10.3389/fimmu.2021.821538</u> .						
310	4.	MacDonald NE, SAGE Working Group on Vaccine Hesitancy Vaccine. Vaccine hesitancy:						
311		Definition, scope and determinants. Vaccine. 2015;33(34):4161-64.						
312		https://doi.org/10.1016/j.vaccine.2015.04.036.						
313	5.	Larson JH, Jarrett C, Eckersberger E, Smith DMD, Paterson P. Understanding vaccine						
314		hesitancy around vaccines and vaccination from a global perspective: a systematic review						
315		of published literature, 2007-2012. Vaccine. 17;32(19):2150-59.						
316		https://doi.org/10.1016/j.vaccine.2014.01.081.						
317	6.	Lazarus JV, Ratzan SC, Adam Palayew A et al. A global survey of potential acceptance of						
318		a COVID-19 vaccine. 2021; 27(2):225-228. <u>https://doi.org/10.1038/s41591-020-1124-9</u> .						
319	7.	Sallam M. COVID-19 vaccine hesitancy worldwide: A concise systematic review of						

320	vaccine	acceptance	rates.	Vaccines	(Basel)	2021;	9(2):160.
321	https://doi	org/10 3390/vac	cines90201	60			


- 322 8. National Academies of Sciences, Engineering, and Medicine; Health and Medicine
- 323 Division; Board on Population Health and Public Health Practice; Board on Health
- 324 Sciences Policy; Committee on Equitable Allocation of Vaccine for the Novel Coronavirus.
- 325 Framework for Equitable Allocation of COVID-19 Vaccine. National Academies Press
- 326 (US); 2020. <u>https://doi.org/10.17226/25917</u>
- 327 9. Okubo R, Yoshioka T, Ohfuji S, Matsuo T, Tabuchi T. COVID-19 Vaccine Hesitancy and
- 328 Its Associated Factors in Japan. Vaccines (Basel) 2021;9(6):662. https://doi.org/
 329 10.3390/vaccines9060662.
- 10. Ishimaru T, Okawara M, Ando H, Hino A, Nagata T, Tateishi S, et al. Gender differences
- in the determinants of willingness to get the COVID-19 vaccine among the working-age
- 332 population in Japan. Hum Vaccin Immunother. 2021;17(11): 3975-81.
 333 https://doi.org/10.1080/21645515.2021.1947098.
- 11. Prime Minister's Office of Japan. About inoculation schedule of COVID-19 vaccine [In
 Japanese].https://www.kantei.go.jp/jp/headline/kansensho/vaccine_supply.html. Accessed
 31 March, 2022.
- 337 12. Ministry of Health, Labour and Welfare. About inoculation to medical staff etc. [In
 338 Japanese]. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine iryoujuujisha.html.

339 Accessed 31 March, 2022.

340	13. Ministry of Health, Labour and Welfare. Notice of inoculation at the workplace [In
341	Japanese]. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_shokuiki.html.
342	Accessed 31 March, 2022.
343	14. Ishimaru T, Nagata M, Hino A, Yamashita S, Tateishi S, Tsuji M. Workplace measures
344	against COVID-19 during the winter third wave in Japan: Company size-based differences.
345	J Occup Health. 2021;63(1):e12224. Hpps://doi.org/10.1002/1348-9585.12224.
346	15. Sasaki N, Imamura K, Kataoka M, Kuroda R, Tsuno K, Sawada U, et al. COVID-19
347	measurements at the workplace in various industries and company sizes: a 2-month follow-
348	up cohort study of full-time employees in Japan. Environ Occup Health Practice. 2021:3.
349	https://doi.org/10.1539/eohp.2020-0017-OA.
350	16. Fujino Y, Ishimaru T, Eguchi H, Tsuji M, Tateishi S, Ogami A, et al. Protocol for a
351	nationwide Internet-based health survey in workers during the COVID-19 pandemic in
352	2020. J UOEH 2021;43(2):217-25. https://doi.org/10.7888/juoeh.43.217.
353	17. Mori K. Current Status and Issues for the Role of Occupational Health Physicians in Japan.
354	2018 JMA Journal. 1(1)15-21. https://doi.org/10.31662/jmaj.2018-0011
355	18. Schmid P, Rauber D, Betsch C, Lidolt G, Denker M-L. Barriers of Influenza Vaccination
356	Intention and Behavior - A Systematic Review of Influenza Vaccine Hesitancy, 2005 -
357	2016. PLoS One. 2017;12:e0170550. https://doi.org/10.1371/journal.pone.0170550.

- 358 19. Gargano LM, Painter JE, Sales JM, Morfaw C, Jones LM, Murray D, et al. Seasonal and
- 359 2009 H1N1 influenza vaccine uptake, predictors of vaccination and self-reported barriers
- to vaccination among secondary school teachers and staff. Hum Vaccin. 2011; 7(1):89–95.
- 361 <u>https://doi.org/10.4161/hv.7.1.13460</u>.
- 362 20. Hak E, Schönbeck Y, De Melker H, Van Essen GA, Sanders EA. Negative attitude of highly
- 363 educated parents and health care workers towards future vaccinations in the Dutch
- 364 childhood vaccination program. Vaccine 2005; 23 (24): 3103-7. https://doi.org/
- 365 10.1016/j.vaccine.2005.01.074.
- 366 21. Wei F, Mullooly JP, Goodman M, McCarty MC, Hanson AM, Crane B, et al. Identification
- and characteristics of vaccine refusers. BMC Pediatr 2009; 9: 18. https://doi: 10.1186/1471-
- 368 2431-9-18.
- 369 22. King WC, Rubinstein M, Reinhart A, Mejia R. COVID-19 vaccine hesitancy January-May
- 370 2021 among 18-64 year old US adults by employment and occupation. Prev Med Rep.
- 371 2021;24:101569. <u>https://doi.org/10.1016/j.pmedr.2021.101569</u>.
- 372 23. Wang K, Wong EL, Ho K, Cheung AW, Yau PS, Dong D, et al. Change of willingness to
- accept COVID-19 vaccine and reasons of vaccine hesitancy of working people at different
- 374 waves of local epidemic in Hong Kong, China: Repeated cross-sectional surveys. Vaccines
- 375 (Basel). 2021;9(1):62. <u>https://doi.org/10.3390/vaccines9010062</u>.
- 376 24. Dorman C, Perera A, Condon C, Chau C, Qian J, Kalk K, et al. Factors associated with

377	willingness to be vaccinated against COVID-19 in a large convenience sample. J
378	Community Health. 2021;46(5):1013-19. <u>https://doi.org/10.1007/s10900-021-00987-0</u> .
379	25. Betsch C, Schmid P, Heinemeier D, Korn L, Holtmann C, Böhm R. Beyond confidence:
380	Development of a measure assessing the 5C psychological antecedents of vaccination.
381	PLos One. 2018;13(12):e0208601. https://doi.org/10.1371/journal.pone.0208601.
382	26. Kang GJ, Culp RK, Abbas KM. Facilitators and barriers of parental attitudes and beliefs
383	toward school-located influenza vaccination in the United States: Systematic review.
384	Vaccine 2017;35(16):1987-95. https://doi.org/10.1016/j.vaccine.2017.03.014.
385	27. Agranov M, Elliott M, Ortoleva P. The importance of Social Norms against Strategic
386	Effects: The case of Covid-19 vaccine uptake. Econ Lett 2021;206:109979. https://doi.org/
387	10.1016/j.econlet.2021.109979.
388	28. Luz PM, Johnson RE, Brown HE. Workplace availability, risk group and perceived barriers
389	predictive of 2016-17 influenza vaccine uptake in the United States: A cross-sectional study.
390	Vaccine. 2017;35(43):5890-5896. https://doi.org/10.1016/j.vaccine.2017.08.078.
391	
392	



396 Figure 1. Flow diagram of the study participants

398 Declarations

- 399 Ethical approval and consent to participate
- 400 This study was approved by the ethics committee of the University of Occupational and
- 401 Environmental Health, Japan (reference nos. R2-079 and R3-006). Informed consent was
- 402 obtained from all participants via the survey website.

403

- 404 Consent for publication
- 405 Not applicable.

406

- 407 Availability of data and material
- 408 Data available on request from authors.
- 409 Competing interests
- 410 The authors declare that they have no competing interests.

411

412 Funding

The study was supported and partly funded by research grants from the University of Occupational and Environmental Health, Japan (no grant number), the Japanese Ministry of Health, Labour and Welfare (H30-josei-ippan-002, H30-roudou-ippan-007, 19JA1004, 20JA1006, 210301-1, and 20HB1004), Anshin Zaidan (no grant number), the Collabo-Health

417	Study Group (no grant number), Hitachi Systems, Ltd. (no grant number), and scholarship
418	donations from Chugai Pharmaceutical Co., Ltd. (no grant number). The funders were not
419	involved in the study design, collection, analysis, or interpretation of data, the writing of this
420	article, or the decision to submit it for publication.
421	
422	Authors' contributions
423	KM designed the analysis, analyzed the data, and wrote the manuscript. TM designed the
424	analysis and reviewed the manuscript. TM created the questionnaire, advised on the study
425	design and data interpretation, and reviewed the manuscript. HA, AH, ST, MT, and SM
426	reviewed the manuscript and advised on the data interpretation. YF was chairperson of the
427	study group, created the questionnaire, advised on the data interpretation, and reviewed the
428	manuscript.
429	
430	Acknowledgments
431	The current members of the CORoNa Work Study, in alphabetical order, are as follows: Dr. Hajime Ando,
432	Dr. Hisashi Eguchi, Dr. Yoshihisa Fujino (present chairperson of the study group), Dr. Arisa Harada, Dr.
433	Ayako Hino, Dr. Kazunori Ikegami, Dr. Tomohiro Ishimaru, Dr. Kyoko Kitagawa, Ms. Ning Liu, Dr. Kosuke
434	Mafune, Dr. Shinya Matsuda, Dr. Ryutaro Matsugaki, Dr. Koji Mori, Dr. Keiji Muramatsu, Dr. Masako
435	Nagata, Dr. Tomohisa Nagata, Dr. Akira Ogami, Dr. Makoto Okawara, Dr. Rie Tanaka, Dr. Seiichiro Tateishi,

- 436 Dr. Shinya Matsuda, Dr. Tomohiro Ishimaru, and Dr. Tomohisa Nagata. All members are affiliated with the
- 437 University of Occupational and Environmental Health, Japan.

439 Table 1. Participant characteristics according to company size

		Size of belonging company (Number of employees)					
		Large (1000 or more) Medium (50-999) Small (1-49)					
Total		4272	5117	6440			
٨٥٩							
Age 2	0-29	185 (4.3%)	259 (5.1%)	173 (2.7%)			
	0-39	611 (14.3%)	764 (14.9%)	769 (11.9%)			
	0-39	1222 (28.6%)	1601 (31.3%)	1898 (29.5%)			
	0-49	1755 (41.1%)	1929 (35.7%)	2511 (39.0%)			
	0-65	499 (11.7%)	664 (13.0%)	1089 (16.9%)			
Sex	A	2791 (65 10/)	2172((2.00/)	2795 (59.90/)			
	Aen Manager	2781 (65.1%)	3172 (62.0%)	3785 (58.8%)			
	Vomen ousehold income (million JPY)	1491 (34.9%)	1945 (38.0%)	2665 (41.2%)			
	· · · · · ·	129 (2.0)	22((4 40/)	((0)(10,20/))			
	<2	128 (3.0)	226 (4.4%)	660 (10.3%)			
	2 and <4	514 (12.0%)	990 (19.3%)	1594 (24.8%)			
	≥ 4 and < 6	828 (19.4%)	1316 (25.7%)	1610 (25.0%)			
	≥ 6 and < 8	997 (23.3%)	1068 (20.9%)	1105 (17.2%)			
	≧8	1805 (42.3%)	1517 (29.6%)	1471 (22.8%)			
	al background						
	unior high or high school	1018 (23.8%)	1426 (27.9%)	2117 (32.9%)			
	/ocational school, junior college	613 (14.4%)	1003 (19.6%)	1575 (24.5%)			
0	r technical school						
U	Jniversity or graduate school	2641 (61.8%)	2688 (52.5%)	2748 (42.7%)			
Marital sta	atus						
Ν	<i>Married</i>	1244 (29.1%)	1704 (33.3%)	2296 (35.7%)			
V	Vidowed/divorced	339 (7.9%)	432 (8.4%)	755 (11.7%)			
N	Jever married	2689 (62.9%)	2981 (58.3%)	3389 (58.3%)			
Occupatio	n						
G	General employee	2104 (49.3%)	2773 (54.2%)	2423 (37.6%)			
	<i>M</i> anager	691 (16.2%)	753 (14.7%)	382 (5.9%)			
	Executive manager	31 (0.7%)	107 (2.1%)	494 (7.7%)			
	Public employee, faculty member, or non-profit	806 (18.9%)	606 (11.8%)	354 (5.5%)			
	rganization employee		000 (11070)	201 (01070)			
	emporary/contract employee	603 (14.1%)	810 (15.8%)	340 (5.3%)			
	ndependent business	9 (0.2%)	15 (0.3%)	1548 (24.0%)			
	commercial and industrial services)) (0.270)	15 (0.570)	15 10 (2 1.070)			
	Small office/home office	3 (0.1%)	3 (0.1%)	270 (4.2%)			
	Agricultural, forestry, and fishing industries	2 (0.0%)	3 (0.1%)	135 (2.1%)			
	rofessional occupation	11 (0.3%)	14 (0.3%)	· · · ·			
		11 (0.5%)	14 (0.3%)	140 (2.2%)			
	lawyer, tax accountant, etc.)	12 (0.20()	22 (0 (0())	254 (5.50/)			
	Other occupation	12 (0.3%)	33 (0.6%)	354 (5.5%)			
Industry	A	10(0 (25 00/)	1170 (22.00/)	755 (11 70/)			
	Aanufacturing	1069 (25.0%)	1179 (23.0%)	755 (11.7%)			
	ublic service	638 (14.9%)	389 (7.6%)	203 (3.2%)			
	nformation and technology	312 (7.3%)	331 (6.5%)	287 (4.5%)			
	Retail and wolesale	244 (5.7%)	355 (6.9%)	629 (9.8%)			
	Eating/drinking	110 (2.6%)	182 (3.6%)	513 (8.0%)			
	Education and religion	275 (6.4%)	417 (8.1%)	507 (7.9%)			
	inance	434 (10.2%)	213 (4.2%)	161 (2.5%)			
	Construction	96 (2.3%)	139 (2.7%)	428 (6.7%)			
	Other	1064 (25.6%)	1912 (37.4%)	2957 (45.9%)			
Vaccinatio	on arranged by company						
Y	<i>Z</i> es	2383 (55.8%)	1780 (34.8%)	914 (14.2%)			
N	Jo	1889 (44.2%)	3337 (65.2%)	5526 (85.8%)			
Month of	2nd COVID-19 vaccination						
F	ebruary-June	161 (3.0%)	205 (4.0%)	197 (3.1%)			
	uly	450 (10.5%)	467 (9.1%)	607 (9.4%)			
	August	1267 (29.7%)	4354 (26.5%)	1550 (24.1%)			
	September	941 (22.0%)	1140 (22.3%)	1380 (21.4%)			
	Detober	774 (18.1%)	1063 (20.8%)	1212 (18.8%)			
	Jovember	240 (5.6%)	319 (6.2%)	420 (6.5%)			
	December	21 (0.5%)	35 (0.7%)	40 (0.6%)			
		418 (9.8%)	534 (10.4%)	1034 (16.1%)			

Second vaccination	model 1			model 2			model 3		
Comp. size	OD	95%CI	P value	OD	95%CI	P value	OD	95%CI	P valu
by July									
Large	Ref.			Ref.			Ref.		
Medium	0.93	0.82-1.05	0.229	0.98	0.86-1.10	0.691	1.06	0.94-1.21	0.330
Small	0.77	069-0.87	< 0.001	0.79	0.69-0.90	0.002	0.94	0.82-1.07	0.350
Vaccination by	comp.						1.56	1.40-1.74	< 0.00
by August									
Large	Ref.			Ref.			Ref.		
Medium	0.87	0.79-0.94	0.001	0.92	0.84-1.00	0.065	1.05	0.96-1.15	0.277
Small	0.67	0.62-0.73	< 0.001	0.76	0.69-0.83	< 0.001	0.98	0.89-1.08	0.692
Vaccination by	comp.						1.98	1.83-2.15	< 0.00
by September									
Large	Ref.			Ref.			Ref.		
Medium	0.86	0.78-0.93	0.001	0.92	0.84-1.01	0.085	1.04	0.95-1.15	0.349
Small	0.64	0.59-0.70	< 0.001	0.77	0.70-0.84	< 0.001	0.97	0.88-1.07	0.541
Vaccination by	comp.						1.90	1.76-2.07	< 0.00
by October									
Large	Ref.			Ref.			Ref.		
Medium	0.92	0.82-1.02	0.127	1.00	0.89-1.12	0.971	1.14	1.01-1.28	0.029
Small	0.54	0.48-0.61	< 0.001	0.75	0.67-0.84	< 0.001	0.95	0.85-1.07	0.377
Vaccination by	comp.						2.05	1.84-2.27	< 0.00
by November									
Large	Ref.			Ref.			Ref.		
Medium	0.93	0.81-1.10	0.218	1.01	0.88-1.15	0.918	1.15	1.01-1.32	0.042
Small	0.54	0.48-0.61	< 0.001	0.73	0.64-0.83	< 0.001	0.94	0.82-1.08	0.362
Vaccination by	comp.						2.14	1.88-2.43	< 0.00
by December									
Large	Ref.			Ref.			Ref.		
Medium	0.94	0.82-1.07	0.329	1.02	0.89-1.17	0.759	1.17	1.02-1.35	0.029
Small	0.54	0.48-0.61	< 0.001	0.73	0.64-0.83	< 0.001	0.93	0.81-1.07	0.317
Vaccination by	comp.						2.14	1.83-2.15	< 0.00

441 Table 2 Association between company size and completion of the second COVID-19 vaccine dose

442 model 1: adjusted for age and sex

443 model 2: model 1+ adjusted for annual household income, education, marital status, occupation and industry

444 model 3: model 2 + adjusted for company-arranged vaccination

445 Size of company: large (1-49); medium-sized (50-999); large (1000 or more)

446 Vaccination by comp.: vaccination arranged by company